

Disclosures

Personal Commercial (23)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|---|
| <i>Self</i> | | | |
| Adrenomed | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Amgen | Data Safety Monitoring Board | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Bayer | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Berlin Cures | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Boston Scientific | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Bristol-Myers Squibb Company | Data Safety Monitoring Board | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| CVRx | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| G3 Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Janssen | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Luitpold Pharmaceuticals, Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Medscape | <i>Other - Medscape on line CME teaching programs</i> | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Medtronics | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Merck & Co., Inc. | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Novartis | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Novartis Corporation | Speaker's Bureau | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Relypsa | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Roche | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Sanofi-Aventis | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Stealth Peptide | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |

| | | | |
|-----------|---------------------------|--------------------------|--|
| Vifor | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| ZS Pharma | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Personal Non-Commercial (8)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|--|
| <i>Self</i> | | | |
| American Heart Association | Other - <i>Deputy Chief Science Officer</i> | Significant (>= \$5,000) | General Cardiology |
| American Heart Journal | Other - <i>Editorial Board</i> | None (\$0) | General Cardiology |
| European Journal of Heart Failure | Other - <i>Associate Editor</i> | None (\$0) | Heart Failure and Cardiomyopathies |
| European Union | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Heart Failure Society of America | Other - <i>Member, Executive Council</i> | None (\$0) | Heart Failure and Cardiomyopathies |
| Journal of American College of Cardiology | Other - <i>Section Editor</i> | None (\$0) | Heart Failure and Cardiomyopathies |
| Journal of the American College of Cardiology Heart Failure | Other - <i>Consulting Editor</i> | None (\$0) | Heart Failure and Cardiomyopathies |
| National Institutes of Health | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |

Clinical Trial Enroller (3)

| Trial Name | Trial Sponsor | Trial Funding Source |
|-----------------|-------------------------------|----------------------|
| ATHENA HF | National Institutes of Health | |
| IRON OUT | National Institutes of Health | |
| PROHIBIT Sodium | National Institutes of Health | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/1/2017

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/1/2017

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 8/1/2017

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 8/1/2017

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.